Pharmacology Drugs of Respiratory system. Drugs acting on respiratory system. Dr. Ahmad Al-Zohyri Lec. 11

Similar documents
RESPIRATORY PHARMACOLOGY - ASTHMA. Primary Exam Teaching - Westmead ED

Respiratory Pharmacology. Manuel Otero Lopez Department of Anaesthetics and Intensive Care Hôpital Européen Georges Pompidou, Paris, France

ASTHMA. Epidemiology. Pathophysiology. Diagnosis. IAP UG Teaching slides

Pharmacology of drugs used in bronchial asthma & COPD

Chapter 7. Anticholinergic (Parasympatholytic) Bronchodilators. Mosby items and derived items 2008, 2002 by Mosby, Inc., an affiliate of Elsevier Inc.

History & Development

Respiratory Pharmacology

Asthma Description. Asthma is a disease that affects the lungs defined as a chronic inflammatory disorder of the airways.

RESPIRATORY PHARMACOLOGY

Chapter 55. Changes in the Airway With COPD. Manifestations of Severe COPD. Drugs Used to Treat Obstructive Pulmonary Disorders

COPD. Breathing Made Easier

Function of the Respiratory System. Exchange CO2 (on expiration) for O2 (on inspiration)

Treatment. Assessing the outcome of interventions Traditionally, the effects of interventions have been assessed by measuring changes in the FEV 1

Clinical Indications. Clinical Indications. RSPT 2317 Methylxanthines. RSPT 2317 Methylxanthines

On completion of this chapter you should be able to: discuss the stepwise approach to the pharmacological management of asthma in children

Medicine Dr. Kawa Lecture 4 - Treatment of asthma :

Drugs acting on the respiratory tract

Medications Affecting The Respiratory System

Lecture Notes. Chapter 3: Asthma

31 - Respiratory System

From the Text. Clinical Indications. Clinical Indications. Clinical Indications. Clinical Indications. RSPT 2317 Methylxanthines

Bronchial Asthma and COPD

Steven Berkowitz, DVM Chief, Emergency and Critical Care Saint Francis Veterinary Center

Lungs SLO Practice (online) Page 1 of 5

Significance. Asthma Definition. Focus on Asthma

Treatment of Cough. Cough is a useful protective reflex. Cough is an indicator of an underlying illness.

Treatment of Cough. Cough is a useful protective reflex. Cough is an indicator of an underlying illness.

Asthma- THE most common Pediatric Disease JENNIFER MCDANIEL, RRT- NPS

Air Flow Limitation. In most serious respiratory disease, a key feature causing morbidity and functional disruption is air flow imitation.

IPRAVENT Respules/Respirator solution (Ipratropium bromide)

1. What is delayed sequence intubation? Can it be used for severe Asthma exacerbation? 2. What about pregnancy and Asthma is so important?

Antiallergics and drugs used in anaphylaxis

Drug Profiles Professional Responder

Impact of Asthma in the U.S. per Year. Asthma Epidemiology and Pathophysiology. Risk Factors for Asthma. Childhood Asthma Costs of Asthma

Systems Pharmacology Respiratory Pharmacology. Lecture series : General outline

Asthma. chapter 7. Overview

Platelet aggregation inhibitor. Cardiac chest pain or suspected Myocardial Infarction.

RESPIRATORY SYSTEM - PHARMACOLOGY-

PHARMACOLOGICAL PROBLEMS

CHRONIC OBSTRUCTIVE PULMONARY DISEASE

3 RESPIRATORY SYSTEM

Utibron Neohaler. (indacaterol, glycopyrrolate) New Product Slideshow

Composition Each ml of Ventol solution for inhalation contains 5 mg Salbutamol (as sulphate).

Respiratory Anesthetic Emergencies in Oral and Maxillofacial Surgery. By: Lillian Han

Analgesic Drugs PHL-358-PHARMACOLOGY AND THERAPEUTICS-I. Mr.D.Raju,M.pharm, Lecturer

Managing Respiratory Symptoms - Breathlessness, Cough and Secretions. Dr Laura Healy. Palliative Medicine Registrar, Beaumont Hospital.

7.2 Part VI.2 Elements for a Public Summary

Basic mechanisms disturbing lung function and gas exchange

2/12/2015. ASTHMA & COPD The Yin &Yang. Asthma General Information. Asthma General Information

VACCINE-RELATED ALLERGIC REACTIONS

Autonomic Nervous System (ANS) وحدة اليوزبكي Department of Pharmacology- College of Medicine- University of Mosul

Foundations of Pharmacology

10/6/2014. Tommy s Story: An Overview of Asthma Mangement. Disclosure. Objectives for this talk.

Overview. The Respiratory System. Chapter 18. Respiratory Emergencies 9/11/2012

Nursing Process Focus: Patients Receiving Salmeterol (Serevent)

Objectives. Case Presentation. Respiratory Emergencies

DR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL

Dr Rodney Itaki Lecturer Division of Pathology Anatomical Pathology Discipline

VENTOLIN RESPIRATOR SOLUTION

Drugs Used to Treat Chronic Obstructive Pulmonary Disease (COPD)

Better Living with Obstructive Pulmonary Disease A Patient Guide

Recurrent wheezing illnesses 24.9% Similar to Australia Above global averages

Asthma/COPD. Asthma synopsis. chronic inflammation of bronchial airways bronchi lining bronchi muscles mucus

Respiratory Pharmacology PCTH 400 Asthma and β-agonists

Emily DiMango, MD Asthma II

Respiratory Therapy. Medical/Scientific/General Background

Monocast Description Indications

Asthma - Chronic. Presentations of asthma Cough Wheeze Breathlessness Chest tightness

NEBULIZED SALBUTAMOL WITH & WITHOUT IPRATROPIUM BROMIDE IN THE TREATMENT OF ACUTE SEVERE ASTHMA

Chapter 8. Learning Objectives. Learning Objectives 9/11/2012. Anaphylaxis. List symptoms of anaphylactic shock

기관지확장제와기관지천식 치료에쓰이는약물 이종호 한림의대약리학교실

Atrovent Administration

RESPIRATORY BLOCK. Bronchial Asthma. Dr. Maha Arafah Department of Pathology KSU

500 micrograms/dose Turbohaler dry powder device 500 micrograms/ml injection. 12 micrograms/dose Turbohaler dry powder device

Chronic obstructive pulmonary disease

Chapter 10 The Respiratory System

Integrated Cardiopulmonary Pharmacology Third Edition

Urticaria Moderate Allergic Reaction Mild signs/symptoms with any of following: Dyspnea, possibly with wheezes Angioneurotic edema Systemic, not local

Decramer 2014 a &b [21]

Respiratory Diseases and Disorders

RESPIRATORY EMERGENCIES. Michael Waters MD April 2004

Bronchial asthma. MUDr. Mojmír Račanský Odd. Alergologie a klinické imunologie FNOL Ústav Imunologie LF UPOL

Asthma training. Mike Levin Division of Asthma and Allergy Red Cross Hospital

Exacerbations. Ronald Dahl, Aarhus University Hospital, Denmark

Agonists: morphine, fentanyl Agonists-Antagonists: nalbuphine Antagonists: naloxone

Asthma Medications: Information for Children and Families. What You Need to Know about Medicines for Asthma

a. Will not suppress respiratory drive in acute asthma

BNF CHAPTER 3: RESPIRATORY

PBL RESPIRATORY SYSTEM DR. NATHEER OBAIDAT

BRICANYL INJECTION. terbutaline sulfate PRODUCT INFORMATION

Exercise-Induced Bronchoconstriction EIB

Medications for Managing COPD in Hospice Patients. Jim Joyner, PharmD, CGP Director of Clinical Operations Outcome Resources

Respiratory Pharmacology. Pharmacology. Clinical Pharmacology. farmakon. pharmakon. Medicine Poison Magic Spell

ASTHMA ASTHMA DISEASE SUMMARY. Risk Factors

PATHOPHYSIOLOGICAL PROCESS TEMPLATE

Lecture Notes. Chapter 9: Smoke Inhalation Injury and Burns

PRODUCT INFOMATION APO-IPRATROPIUM SOLUTION

PACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP

COUGH PROF. G. ZULIANI

COPD. Helen Suen & Lexi Smith

Transcription:

Drugs acting on respiratory system

Dr. Ahmad Al-Zohyri Lec. 11 Respiratory system is subjected to a lot of injurers and harms because it is nearly the only system which is in continuous contact with the external environment during the whole life of human being. As a result respiratory system is subjected to pollution smoke, chemicals dust, & microorganism which means it is subjected to everything in the environment. Drugs that are used for treatment of respiratory problems include 1. Drugs & air flow obstruction. 2. Oxygen. 3. Respiratory stimulants. 4. Expectorants & cough suppressant. Drugs & air flow obstruction The aim of treatment in air flow obstruction is to increase ventilation by reducing bronchial smooth m. tone with specific agonist & antagonist drugs, by blocking the mechanisms of allergic response. Drugs used in the treatment of airways obstruction are:

1. B 2 - Adrenoceptors agonist or stimulants: The mechanism of action is by increasing camp in the bronchial smooth muscles and mast cell leading to bronchodilation. 2. Theophylline and other xanthine derivatives: they act by blocking the enzyme phosphodiesterase leading to increase intracellular camp. 3. Mast cell membrane stabilizers: as Na cromoglycate [cromolyn], they prevent the release of broncho constrictor mediators. 4. Corticosteroids: they stabilize mast cell and improve the pulmonary function in extrinsic and intrinsic asthma by other mechanisms not well understood. 5. Anti-cholinergic drugs: they act by decreasing muscarinic bronchoconstriction. 1) B 2 - Adrenoceptors agonists or stimulants: A. Salbutamol: Mechanism of action: Agents as salbutamol, terbutaline and fenoterol are selective stimulants of B 2 receptors; they act on these receptors in bronchi and small airways and on mast cells. They cause fewer side effects on heart than adrenadine or isoprenaline which are non-selective (obsolete). Action: 1. Relaxation of bronchial smooth muscles. 2. Stabilization of mast cells. Route of administration: Salbutamol is best given by inhalation because: 1. It permits direct delivery of the drug to the site of action. 2. It reduces the possibility of general systemic side effect.

3. The total dose administered is very small and this further limit the adverse effects. 4. It provides large surface area for absorption. 5. Rapid onset of action. Salbutamol has a relativity long duration of action of about 4 hours or even longer. Side effect: 1. Tremor due to Stimulation of B 2 receptors. 2. Other does-dependent effects resulting from weak activation of B- receptor as tachycardia and hypokalemia, these are rare however with higher degree of selectivity afforded by aerosol route. Note: Dose dependent means occur or increase when increase in dose. Clinical Uses: 1. In asthma. 2. In chronic obstructive airways disease (long-term treatment and prophylactic), or maintenance therapy (aerosol or oral tablets) or in acute attacks by nebulizers. B. Terbutaline & Fenoterol: They are selective B 2 - receptor stimulants (Agonist) with actions similar to salbutamol they are available as oral, parenteral & inhalation preparations and their adverse effects and indications are similar to those of salbutamol. C. Other selective B 2 stimulants: Isoetharine, rimiterol, and reproterol are either less selective or short acting and have no clear advantage over salbutamol and terbutaline. Notes:

B 2 agonist given as aerosol inhalation result in symptomatic relief with minimum cardiac adverse effects especially in patient with reversible airways obstruction. Response depends on the patient using the aerosol correctly, even with optimal use only 10% of the drug is inhaled while the remaining 90% is swallowed or metabolized. 2) Theophylline & other Xanthine derivatives: Mechanism of the action: By inhibition of phosphodiesterase and thus increasing camp cone. by blocking the enzyme that breaks down the nucleotide. Increased camp reduce the tone in bronchial smooth m. and stabilizes mast cell membrane. Xanthine may have wide spread effect on s.m. not only in bronchi but also in CVS. Kinetics: Theophylline is well absorbed from the gut and it is extensively metabolized in the liver, difference in the hepatic metabolism are the principle reason for the wide variation in kinetics both between individuals and within the same individual during the course of illness. Average t1/2 in adult is about 8-12hr so it is given 2-3 times daily. Adverse effect: Tachycardia and palpitation at therapeutic doses. Nausea. vomiting and diarrhea at high therapeutic doses and convulsions are associated with plasma level above 30µg/l. Clinical Uses: It is used orally in long term treatment of asthma & Chronic obstructive airways diseases (COAD) especially in patient who show response to it. Aminophylline:

It consists of theophylline and ethylene diamine in ratio of 2:1 it is used in: 1. Severe acute attacks of asthma & status asthmatics. 2. Exacerbation of COAD. 3. Acute left ventricular failure with pulmonary edema. Oral theophylline preparations are useful in long-term treatment of asthma & reversible (COAD). A useful bronchodilation response can be often achieved with in the therapeutic range & the S/E can be minimized with the aid of plasma level measurements. 3) Mast cell membrane stabilizers: As Na cromoglycate (cromolyn) & Ketotifen. They are not bronchodilators but they prevent bronchoconstriction in patient with extrinsic (allergic) asthma which is caused by pollen & allergic agents. They stabilize sensitized mast cell and inhibit the release if bronchoconstrictor agent like: histamine, SHT (serotonin) & SRS-A (slow reacting substances for anaphylaxis) as leukotrines. Mast cell stabilizers are useful in extrinsic (Allergic) asthma particularly in children & young adults & can prevent exercise induced asthma. Response in intrinsic asthma is usually disappointing and these agents have nothing to offer to patients with (COAD). Clinical uses: Na Cromoglycate is administered locally to the lung by inhalation as powder or from pressurized aerosols or nebulizers. Ketotifen: It is a histamine Hl - receptor blocker which may also has some antiasthmatic effect. But it effect or benefit has not been conclusively demonstrated. In common with other anti-histamine it causes drowsiness.

Ketotifen is given orally as tablets or capsules. Side effect: sedation & dry mouth that result from additional antihistamine... effect of these drugs. 4) Corticosteroids: The actions on the bronchi is not fully understood, their effect are the result of the following action: a. Anti-inflammatory (for any reason). b. Reduction of mucosal oedema increase airflow. c. Modification of immune response & stabilization of mast cells. d. Increase B 2 - receptor responsiveness to agonist In the management of airway obstruction they are given by inhalation orally and IV according to the condition: A. Inhalation: Steroid inhalation represent a significant advance in the management of bronchospasm because of the adverse effect associated with systemic steroid are minimized (steroids are highly toxic drugs). Beclomethasone & betamethasone & administered by aerosol inhalant Adverse effects: they are usually very much less than those of systemic agents but infection of pharynx & larynx with candidiasis may occur (disadvantage). Aerosol inhalation corticosteroid should replace long term oral corticosteroid therapy wherever possible as the benefit can be attained without adverse effects of long term systemic steroid treatment B. I.V corticosteroids: When there is sever unresponsive asthma, especially when there is respiratory failure. Hydrocortisone (cortisol) is given I.V.

There is a delay in the onset of any steroid induced bronchodilation & this occurs because the receptors of steroid are found inside cytoplasm and thus they need more time to exert their effect for this reason Hydrocortisone is not used in case of emergency in addition to that other measures should be pursued at the same time. C. oral corticosteroid: Patients with severe exacerbation of asthma require high doses of prednisolone by mouth after I.V hydrocortisone. 5) Anti-cholinergic drugs: Ipratropium: Mechanism of action: The parasympathetic cholinergic bronchoconstrictor effect can be blocked by the use of atropine like drugs, usually this effect of anticholinergic on airway resistance is less than that of sympathetic stimulant agents. Adverse effect: The anticholinergic adverse effects of synthetic derivatives ipratropium bromide are much less than those of atropine itself, it is given by pressurized aerosols or from nebulizers. Oxygen When O2 is given to supplement the amount normally present in the inspired air it should be regarded as drug. It is given in tow forms: 1. High cone. as possible 2. Low cone. (controlled) (24 %-28%) 1. High O2 cone. :

It should be given to all hypoxic patients except those with established potential narcosis. Any apparatus which provide O2 flow to the oro-nasal area at a rate of 5 liters/min or more is effective in supplying a high cone. of O2 in the inspired gas. Indications: a. Pneumonia. b. Acute pulmonary edema. c. Pulmonary thrombo-embolism. d. Fibrosing alveolitis. e. Status asthmaticus. f. respiratory failure or arrest due to drug over dose. g. Acute circulatory failure. h. Cyanide and CO poisoning. 2. low O2 cone. : Usually reserved for patients with exacerbation of COPD with respiratory failure. Ventilation is then ineffective because CO 2 excretion is not maintained in spite of the raised PCO 2 The increaser PCO2 lead to less of sensitivity of respiratory center to CO 2, and. dependence on low arterial PO2 to drive ventilation. High cone. of O2 administered lead to further suppression of ventilation by the removal of the hypoxic drive. Further CO 2 accumulate then rapidly produces narcosis & death. Low con. May be administered by masks using the ventori principle to supply a calibrated inspired O 2 conc. Of 24-28% Respiratory stimulant Some patients with respiratory failure requires Intubations and artificial ventilation. The place of respiratory stimulants is controversial. They may occasionally lead to improvement in ventilation & obviate the need for assisted respiration.

Nikethamide: It is a convulsant or analeptic used in sub-convulsive doses. It's central activity is not selective for the respiratory center Its effect is transient lasting about 5 minutes. Adverse effect include vomiting I restlessness and convulsion. It may be used in respiratory depression following lrappropriate O2 therapy. Ooxapram: It acts like nikethamide but it is given by continuous IV infusion It is used to stimulate respiration in patients who fail to ventilate spontaneously after general anesthesia or in chronic respiratory failure with CO2 retention. Expectorants & cough suppressant These are two other classes of drugs commonly used in respiratory disease; but their therapeutic value is doubtful. Expectorants: Difficulty in bringing up sputum is a common complaint, but there is no evidence that any agent given by any route specifically promoted expectoration of bronchial secretions. Agents with expectorant properties as ammonium chloride & guaniphesin are often included in cough mixtures. Agents claimed to possess a mucolytic properties such as acetyl cysteine haven't been conclusively shown to show any important role in the management of airway obstruction, their beneficial effect may be attributed to the inhalation of steam or water by aerosol rather than the pharmacological properties of the concerned drugs. Cough suppressant (Antitussive):

Cough is a frequent complaint or secondary to an upper respiratory tract infection. Chronic persistent cough is often caused by cigarette smoking. In acute respiratory infection, cough is a useful protective mechanism enabling the clearing the secretions from trachea and bronchi. Cough usually improves spontaneously with treatment of any underlying bacterial infection. Patients with terminal lung cancer with bronchial obstruction or tumor involvement of afferent (sensory) nerve from the lung and chest wall may develop persistent distressing cough this is one of few conditions in which the symptomatic treatment of cough can be completely justified. Cough suppressants are opiate agonists & the suppression of cough reflexes is only part of the narcotic induced depression of the CNS. Drugs used of cough suppression are usually given in the form of a sweet syrup or linctus, although oral or parental opiate will block cough reflexes justified as effective examples are: Diamorphine, Methadone, and Codeine phosphate. New Bronchodilotors or leukotriens antagonists: They are two classes: 1) Cysteinylleukotrien receptor antagonist: Zafirlucost: A potent competitive antagonist at L T04 receptor. It prevents aspirin sensitive asthma & antigen induced and exercise induced bronchospasm. It relaxes airway in mild asthma with activity of 1/3 than that of salbutamol, it is better to be used with B2 receptor agonist (additive effect). 2) 5-Lipoxygenase inhibitor: The act by preventing the production of L TCIY 04, B4 (C4 and 04 are the most potent).

Zeleulin: The prototype compound. It blocks antigen & exercise induced broncrospasm & may inhibit or ' reduce late phase inflammation. It is taken orally with low potency and short t1/2, so it is used in large dose 3-4 times daily. CHW Ali Mazin IBO Ibrahim Ghazi